Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
53 Cards in this Set
- Front
- Back
What drugs are opiod analgesics? (7)
|
Morphine
Fentanyl Codeine Heroin Methadone Meperidine Dextromethorphan |
|
MOA of opioid analgesics?
|
Act as agonists at opioid receptors (mu = morphine, delta = enkephalin, kappa = dynorphin) to modulate synaptic transmission.
|
|
Clinical use of opioid analgesics?
|
-Pain
-Cough suppression (dextromethorphan) -Diarrhea (loperamide and diphenoxylate), -Acute pulmonary edema -Maintenance programs for addicts (methadone). |
|
Toxicity of opioid analgesics?
To what does tolerance NOT develop? |
Addiction
Respiratory depression Constipation Miosis (pinpoint pupils) Additive CNS depression with other drugs Tolerance does not develop to miosis and constipation. |
|
How is opioid analgesic toxicity treated?
|
Toxicity treated with naloxone or naltrexone (opioid receptor antagonist).
|
|
What is contraindicated in a morphine overdose?
|
Oxygen is contraindicated in morphine overdose, b/c/ it may contribute to respiratory failure.
|
|
What drugs are NSAIDS? (4)
|
-Ibuprofen
-Naproxen -Indomethacin -Ketorolac |
|
MOA of NSAIDS? (2)
|
Reversibly inhibit cyclooxygenase (both COX-1 and COX-2).
Block prostaglandin synthesis. |
|
Clinical use of NSAIDS? (3)
|
Antipyretic
Analgesic Anti-inflammatory |
|
Toxicity of NSAIDS? (4)
|
Renal damage
Aplastic anemia GI distress Ulcers |
|
What drugs are COX-2 inhibitors?
|
-Celecoxib
-Valdecoxib |
|
MOA of COX-2 inhibitors?
Why are these drugs less corrosive on the GI lining than other NSAIDS? |
Selectively inhibit cyclooxygenase (COX) isoform 2, which is found in inflammatory cells and mediates inflammation and pain; spares COX-1, which helps maintain the gastric mucosa. Thus, should not have the corrosive effects of other NSAIDs on the GI lining.
|
|
Clinical use of COX-2 inhibitors? (2)
|
-Rheumatoid arthritis
-Osteoarthritis |
|
Toxicity of COX-2 inhibitors?
|
Similar to other NSAIDs; may have less toxicity to GI mucosa (i.e., lower incidence of ulcers, bleeding).
|
|
MOA of Acetaminophen?
Where in the body does it act most? |
Reversibly inhibits cyclooxygenase, mostly in CNS.
Inactivated peripherally. |
|
Clinical use of Acetaminophen? (2)
|
Antipyretic, analgesic, but lacking anti-inflammatory properties.
|
|
Toxicity of Acetaminophen?
What is the antidote? |
Overdose produces hepatic necrosis; acetaminophen metabolite depletes glutathione and forms toxic tissue adducts in liver.
N-acetylcysteine is antidote––regenerates glutathione. |
|
What are 3 drugs used for gout?
|
-Colchicine
-Probenicid -Allopurinol |
|
Colchicine:
-clinical use? -MOA? -S/Es? What drugs is less toxic and thus more commonly used? |
Acute gout.
Depolymerizes microtubules, impairing leukocyte chemotaxis and degranulation. GI side effects, especially if given orally. (Note: indomethacin is less toxic, more commonly used.) |
|
Probenicid:
-use? -MOA? what drug does it inhibit the secretion of? |
Chronic gout.
Inhibits reabsorption of uric acid Also inhibits secretion of penicillin. |
|
Allopurinol:
-uses? (3) -MOA? |
Chronic gout.
Inhibits xanthine oxidase, ↓ conversion of xanthine to uric acid. Also used in lymphoma and leukemia to prevent tumor lysis–associated urate nephropathy. |
|
See diagram in Gout drugs section.
|
See diagram in Gout drugs section.
|
|
MOA of Etanercept?
|
Recombinant form of human TNF receptor that binds TNF-α.
|
|
Clinical use of Etanercept? (3)
|
Rheumatoid arthritis
Psoriasis Ankylosing spondylitis |
|
MOA of Infliximab?
|
TNF-α antibody.
|
|
Clinical use of Infliximab? (3)
|
Crohn’s disease
Rheumatoid arthritis Ankylosing spondylitis |
|
Immunosuppresive agent: Prednisone
It blocks what parts of the inflamm pathway? (2) |
-proliferation
-tissue injury |
|
Immunosuppresive agent: Cyclosporine
It blocks what parts of the inflamm pathway? (2) |
-proliferation
-differentiation to T-cells or antibody |
|
Immunosuppresive agent: Azathioprine
It blocks what parts of the inflamm pathway? (1) |
proliferation
|
|
Immunosuppresive agent: Methotrexate
It blocks what parts of the inflamm pathway? (1) |
proliferation
|
|
Immunosuppresive agent: Dactinomycin
It blocks what parts of the inflamm pathway? (2) |
-proliferation
-differentiation synthesis |
|
Immunosuppresive agent: Cyclophosphamide
It blocks what parts of the inflamm pathway? (1) |
proliferation
|
|
Immunosuppresive agent: Antilymphocytic globulin and monoclonal T-cell antibodies
It blocks what parts of the inflamm pathway? (3) |
-antigen recognition (B and T-cells)
-proliferation -differentiation synthesis |
|
Immunosuppresive agent: Rh3(D) immune globulin
It blocks what parts of the inflamm pathway? (1) |
-antigen recognition (B and T-cells)
|
|
Immunosuppresive agent: Tacrolimus
It blocks what parts of the inflamm pathway? (1) |
cytokine secretion!
|
|
MOA of Cyclosporine?
|
Binds to cyclophilins. Complex blocks the differentiation and activation of T cells
by inhibiting calcineurin, thus preventing the production of IL-2 and its receptor. |
|
Clinical use of Cyclosporine? (2)
|
-Suppresses organ rejection after transplantation
-Selected autoimmune disorders. |
|
Toxicity of Cyclosporine? (3)
|
Predisposes patients to viral infections and lymphoma
Nephrotoxic (preventable with mannitol diuresis). |
|
MOA of Tacrolimus (FK506)?
|
Similar to cyclosporine; binds to FK-binding protein, inhibiting secretion of IL-2 and other cytokines.
|
|
Clinical use of Tacrolimus (FK506)?
|
Potent immunosuppressive used in organ transplant recipients.
|
|
Toxicity of Tacrolimus (FK506)? (5)
|
Significan:
Nephrotoxicity Peripheral neuropathy Hypertension Pleural effusion, Hyperglycemia |
|
MOA of Azathioprine?
What is it toxic to? |
Antimetabolite derivative of 6-mercaptopurine that interferes with the metabolism and synthesis of nucleic acids.
Toxic to proliferating lymphocytes. |
|
Clinical use of Azathioprine? (2)
|
Kidney transplantation
Autoimmune disorders (including glomerulonephritis and hemolytic anemia). |
|
Toxicity of Azathioprine?
What drug may increase toxic effects if used in combo? |
Bone marrow suppression.
Active metabolite mercaptopurine is metabolized by xanthine oxidase; thus, toxic effects may be ↑ by allopurinol. |
|
Clinical use of Aldesleukin (IL-2)? (2)
|
-Renal cell carcinoma
-Metastatic melanoma |
|
Clinical use of Erythropoietin (epoetin)?
|
anemias (especially in renal failure)
|
|
Clinical use of Filgrastim (granulocyte colony-stimulating factor)?
|
Recovery of bone marrow
|
|
Clinical use of Sargramostim (granulocyte-macrophage colony-stimulating factor)?
|
Recovery of bone marrow
|
|
Clinical use of α-interferon? (4)
|
Hepatitis B and C
Kaposi’s sarcoma Leukemias Malignant melanoma |
|
Clinical use of β-interferon?
|
Multiple sclerosis
|
|
Clinical use of γ-interferon?
|
Chronic granulomatous disease
|
|
Clinical use of Oprelvekin (interleukin-11)?
|
thrombocytopenia
|
|
Clinical use of Thrombopoietin?
|
thrombocytopenia
|